A presentation is planned to update the public on progress of the Smoky Hill River Renewal Project. The City of Salina and ...

Late-Breaker Presentation Details Presentation Title: A randomised, double-blind, placebo-controlled, phase II trial assessing the safety and efficacy of EBX-102-02, an oral full-spectrum intestinal ...

In its 2024-25 budget, the government announced the Punjab Horticulture Advancement and Sustainable Entrepreneurship (PHASE) scheme with an allocation of Rs 5 crore. In its earlier budget, (in 2023-24 ...

The City of Corpus Christi will start a significant repaving project on Everhart Road on Monday ... The repaving work will be executed in two phases. Crews will first tackle the segment from ...

This allows the Liverpool Bay CCS project to move into the construction phase, unlocking investments in supply chain contracts, the majority of which will be spent locally, according to Eni.

Topas Therapeutics today announced that it will present clinical Phase 2a data on its lead candidate ... The abstract was selected for presentation in two sessions at DDW. Further details are ...

TURKU, FI / ACCESS Newswire / April 24, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that new Phase II data ...

Xilio Therapeutics, Inc. announced that it will present updated data from its Phase 2 clinical trial ... 2025 ASCO Annual Meeting in Chicago. The presentation is scheduled for May 31, 2025.

Strasbourg, France, April 23, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will be ...

Details from the presentations will be available following ... other than serving as the national principal investigator for Candel’s phase 3 clinical trial of CAN-2409 in patients with ...

Presentation Details: Presenting Author: Andrew T. Kuykendall, M.D. (Moffitt Cancer Center) Title: Results From VERIFY, a Phase 3, Double-Blind, Placebo (PBO)-Controlled Study of Rusfertide for ...

Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in ...